You are here: Industry Insights > cancer

News List

Cancer Survivors Gain From Web-Based Health Care drugs.com
February 13, 2017
Online- and phone-based health care offers a number of benefits for cancer survivors, British researchers report.
GW planing to test its cannabinoids in cancer pharmatimes
February 10, 2017
GW Pharma is strengthening its focus on oncology after promising mid-stage data for its cannabis-based therapy in patients with a rare and aggressive brain tumour called glioblastoma multiforme (GBM).
An alternative theory on how aspirin may thwart cancer worldpharmanews
February 10, 2017
Studies abound that point to a role for plain old aspirin in keeping deadly cancers at bay. While aspirin is not yet part of mainstream treatment for any cancer, it is recommended by the U.S. Preventive Services Task Force for certain adults to help preve
Potential new cancer treatment activates cancer-engulfing cells worldpharmanews
February 07, 2017
Macrophages are a type of white blood cell that can engulf and destroy cancer cells. A research group discovered that by using an antibody for a particular protein found on macrophages, the macrophage is activated, and cancer cells are effectively elimina
Scientists use large data to map links between cell shape and genes pharmaceutical-technology
February 06, 2017
Scientists at the Institute of Cancer Research, London, have used large sets of data to create a map to understand the link between the shape of breast cancer cells and genes.
FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC pharmaceutical-technology
February 06, 2017
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Opdivo injection (nivolumab) for intravenous use in previously treated, locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer.
Mental Health May Affect Chances Against Cancer drugs.com
January 26, 2017
Anxiety and depression may increase the risk of death from certain cancers, early research suggests.
Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to Se firstwordpharma
January 25, 2017
Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today a total of $26 million of invested private capital, led by
Hope Biosciences Licenses nuc-Gemcitabine, A ’Trojan Horse’ Anti-nucleolin-Gemcitabine Aptamer Drug firstwordpharma
January 24, 2017
HOPE BIOSCIENCES announced today that it has acquired the exclusive rights to develop and commercialize nuc-gemcitabine™ (APTA-12/HOPE-888) through a licensing agreement with AptaBio Therapeutics, a Korean pharmaceutical company.
First of its kind cancer stem cell research unlocks clues to treatment resistance firstwordpharma
January 22, 2017
Study data published in the journal Oncotarget suggest that a molecule lost from cancer stem cells, called miR-17, is important in driving oesophageal tumour resistance to radiotherapy, ScienceDaily reported.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page